Core Viewpoint - Cangzhou Pharmaceutical (00867) is rated "Buy" by Cinda Securities, with projected revenue growth from 2025 to 2027 at 10%, 20%, and 22% respectively, and net profit growth at 0%, 15%, and 21% respectively, indicating strong long-term growth potential for the company [1][2]. Group 1: Company Overview - Cangzhou Pharmaceutical, founded in 1992, has transformed from a drug agency to an innovative comprehensive pharmaceutical enterprise, positioning itself as a leading commercial player in the domestic market [2]. - The company faced revenue declines in 2023-2024 due to the impact of national centralized procurement policies, but is expected to recover in 2025 with stabilization in core businesses and rapid growth in emerging sectors [2]. Group 2: Commercialization and Market Strategy - The company boasts a robust commercialization capability with a professional team of approximately 4,700, covering over 50,000 hospitals and medical institutions in China, as well as around 300,000 retail pharmacies and major e-commerce platforms [3]. - Cangzhou has established a comprehensive R&D, registration, commercialization, and production layout in the Southeast Asian market, creating a sustainable second growth curve [3]. Group 3: Business Segments - The company operates four main business segments: 1. Cardiovascular diseases, accounting for about 48% of revenue, with recovery from procurement impacts and rapid growth of innovative products [4]. 2. Digestive and autoimmune diseases, contributing approximately 30% of revenue, supported by exclusive products and new innovations [4]. 3. Skin health, representing about 11% of revenue, with significant potential from newly approved products and plans for separate listing [4]. 4. Ophthalmology, making up around 8% of revenue, with competitive product offerings including exclusive eye drops and newly introduced anti-VEGF drugs [4]. Group 4: Innovation Pipeline - The company has developed nearly 40 innovative pipelines, entering a phase of significant results, with six innovative drugs already commercialized [5]. - Key products in the NDA stage include treatments for acute ischemic stroke, chronic kidney disease anemia, rabies exposure, tetanus, Alzheimer's disease, and atopic dermatitis, with peak sales potential exceeding 10 billion [5].